Biovica attended the Serendipity Bee summit 2014

Biovica attended the Serendipity Bee summit November 11, 2014 in Stockholm. “The summit was a great opportunity for us to present Biovica and network with investors and similar companies in the Nordic region. We where very excited to be selected, especially now when Biovica is entering a new phase of collaborations with pharmaceutical companies and leading [...]

November 12th, 2014 08:49|News|

Biovica receives EU funding for DiviTum™

The European Commission has selected Biovicas project “Clinical validation of the DiviTum™ assay in key European markets” to be funded through the Research and Innovation Framework Program Horizon 2020.   A total of 2 666 proposals were submitted to the first SME (Small Medium Enterprises) Instrument Calls within the European Commission´s R&D Program Horizon 2020. [...]

October 8th, 2014 11:45|News|

Biovica participates at the Nordic Life Science Days 2014

Biovica will participate at the Nordic Life Science Days 7-9 September, 2014. The meeting is a good opportunity for Biovica to network with potential partners for collaboration in the launch of the improved DiviTum Assay. DiviTum is the most sensitive and precise test in the world to measure cell growth rate in a simple blood [...]

July 28th, 2014 11:00|News|

Introducing the improved version of DiviTum™

The new DiviTum™ assayDiviTum™ is CE-labelled and is the most sensitive and precise test in the world to measure cell growth rate in a simple blood sample. The clinical benefit of DiviTum™ in predicting response to therapy and monitoring treatment in cancer is supported by more than 10 studies in peer-reviewed journals.   The new version of the DiviTum™ [...]

July 1st, 2014 11:00|News|

A blood sample can give better information on how effective lung cancer therapies are

A study presented in Barcelona at the International Society of Oncology and Biomarkers Meeting (March 14-18, 2014) demonstrates that a simple blood test can be used to give more comprehensive information on whether chemotherapy against lung cancer will be effective or not. The study included 324 lung cancer patients and blood samples were taken before and during treatment. The blood [...]

March 17th, 2014 11:00|News|

DiviTum identifies women with high risk of developing breast cancer

Women with mutations in certain genes are predisposed to a high risk of breast cancer (about 50%) up to an age of 70 years. A study published by Dr Benjamin Nisman and colleagues have found that DiviTumTM, Biovicas high-precision test to measure cell growth rate, is important when identifying women with high risk to develop [...]

November 20th, 2013 11:00|News|

First study with Karolinska Institutet published

In the clinical trial collaboration programme between Biovica and Karolinska Institutet, the results from the first study have now been published by the scientific journal Breast Cancer Research and Treatment; http://www.ncbi.nlm.nih.gov/pubmed/23736998. Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. [...]

June 14th, 2013 11:00|News|

Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy

Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. The results are being presented at the IMPAKT scientific conference in Brussels, May 2-4. The analysis measures growth rate and this is the first time ever that one test have documented [...]

May 2nd, 2013 11:00|News|